Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 12/20 | 0.78 |
| ▸ | METAP2 | P50579 | 9/20 | 0.78 |
| ▸ | METAP1 | P53582 | 7/20 | 0.78 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | PKM | P14618 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692552 | 1.00 | CBFB (0.78) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL4812598 | 0.92 | CBFB (0.67) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL13866553 | 0.84 | NPC1 (0.74) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL4812027 | 0.84 | METAP2 (0.55) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL124228 | 0.83 | CBFB (1.00) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL13866537 | 0.82 | NPC1 (0.81) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL8556415 | 0.82 | METAP2 (0.78) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL124267 | 0.82 | CBFB (0.78) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL12943863 | 0.82 | METAP2 (0.67) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL12544900 | 0.82 | METAP2 (0.67) | CBFBMETAP2METAP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024451-A | Preparation method and application of 2- (2-pyridyl) benzimidazole derivative curcumin copper complex | 广西师范大学 | 2023-11-10 | — | — | CN | claimed |
| CN-117024451-A | Preparation method and application of 2- (2-pyridyl) benzimidazole derivative curcumin copper complex | 广西师范大学 | 2023-11-10 | — | — | CN | disclosed |
| EP-3180004-B1 | CANCER THERAPEUTICS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3180004-B1 | CANCER THERAPEUTICS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3670509-A1 | INHIBITORS OF INV(16) LEUKEMIA | The University of Virginia Patent Foundation (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10562890-B2 | Cancer therapeutics | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562890-B2 | Cancer therapeutics | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-02-18 | — | — | US | disclosed |
| US-9926290-B2 | Inhibitors of INV(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926290-B2 | Inhibitors of INV(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
| US-9221764-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221764-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8748618-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748618-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2010132684-A9 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010132684-A2 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | CBFB 2/4885METAP2 4282/4885METAP1 3637/4885 |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885METAP2 3332/4885METAP1 2810/4885 |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885METAP2 3287/4885METAP1 2794/4885 |
| US-10562890-B2 | Cancer therapeutics | RUNX1, CBFB, MCL1 | CBFB 2/4885METAP2 4282/4885METAP1 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.